IPSC
Century Therapeutics, Inc. NASDAQ Listed Jun 18, 2021$1.96
Pre-mkt
$1.96
+0.00%
Mkt Cap $169.7M
52w Low $0.43
58.5% of range
52w High $3.04
50d MA $2.19
200d MA $1.82
P/E (TTM)
—
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.3x
ROE
-6.0%
P/FCF
-1.6x
RSI (14)
39.20
ATR (14)
$0.12
Beta
1.67
50d MA
$2.19
200d MA
$1.82
Avg Volume
894.8K
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
3675 Market Street · Philadelphia, PA 19104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | TNS | -0.11 | -0.17 | -54.5% | — | — | — | — | — | — | — | — |
| May 13, 2026 | TNS | -0.15 | -0.11 | +26.7% | 2.29 | +0.4% | -0.4% | +4.4% | -1.7% | -2.6% | -7.0% | — |
| Mar 12, 2026 | TNS | -0.28 | -0.25 | +10.7% | 2.50 | -0.8% | -6.4% | +3.8% | -5.8% | +0.4% | +8.3% | — |
| Nov 13, 2025 | TNS | -0.39 | -0.32 | +17.9% | 0.46 | +3.3% | +1.7% | +1.7% | +2.0% | +5.5% | -5.1% | — |
| Aug 14, 2025 | TNS | -0.38 | -0.38 | +0.0% | 0.55 | +4.2% | +2.1% | +2.2% | -4.2% | -0.9% | -0.7% | — |
| May 15, 2025 | TNS | -0.31 | 0.89 | +387.1% | 0.52 | +0.0% | +8.2% | -1.0% | +8.2% | -3.4% | -0.9% | — |
| Mar 19, 2025 | TNS | -0.45 | -0.43 | +4.4% | 0.58 | -1.5% | -5.7% | +0.9% | +5.2% | -5.0% | +0.2% | — |
| Nov 5, 2024 | TNS | -0.46 | -0.37 | +19.6% | 1.33 | +9.0% | +4.5% | +5.0% | -1.4% | +2.1% | -4.1% | — |
| Aug 8, 2024 | TNS | -0.50 | -0.38 | +24.0% | 1.80 | +2.8% | -4.4% | -3.5% | -0.6% | -5.5% | +6.4% | — |
| May 9, 2024 | TNS | -0.50 | -0.45 | +10.0% | 3.04 | +0.3% | +3.0% | -4.2% | +5.0% | -1.9% | +1.3% | — |
| Mar 14, 2024 | TNS | -0.56 | -0.49 | +12.5% | 4.51 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% | — |
| Nov 9, 2023 | TNS | -0.53 | -0.55 | -3.8% | 1.39 | +4.3% | -7.2% | -0.8% | +2.3% | -0.8% | +2.3% | — |
| Aug 9, 2023 | BMO | -0.54 | -0.56 | -3.7% | 2.85 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% | — |
| May 11, 2023 | AMC | -0.53 | -0.53 | +0.0% | 3.37 | +1.5% | -2.7% | +0.9% | -3.9% | -2.5% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | Mizuho | Initiates | Outperform | $8 | $2.17 | $2.32 | +6.9% | +6.5% | +3.0% | +2.9% | -3.7% | -8.1% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.45 | +4.7% | -1.7% | +6.1% | -7.4% | -1.8% | +1.4% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.17 | $2.13 | -1.8% | -11.5% | +6.2% | +13.2% | +4.8% | +6.6% |
| Nov 17 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.47 | $0.47 | -0.2% | +1.7% | +2.0% | +5.5% | -5.1% | -0.1% |
| May 16 | Chardan Capital | Maintains | Buy → Buy | — | $0.52 | $0.52 | +0.0% | +8.2% | -1.0% | +8.2% | -3.4% | -0.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.47 | $0.46 | -2.1% | -2.3% | -4.3% | -6.1% | -5.6% | +7.6% |
| Mar 28 | Guggenheim | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.2% | -6.5% | -7.2% | -5.1% | +4.0% | -2.3% |
| Mar 24 | Chardan Capital | Maintains | Buy → Buy | — | $0.56 | $0.57 | +2.7% | +5.2% | -5.0% | +0.2% | -1.4% | -6.5% |
| Mar 21 | Guggenheim | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.2% | +0.9% | +5.2% | -5.0% | +0.2% | -1.4% |
| Mar 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.58 | $0.57 | -1.5% | -5.7% | +0.9% | +5.2% | -5.0% | +0.2% |
| Jan 22 | Guggenheim | Maintains | Buy → Buy | — | $0.90 | $0.93 | +3.7% | -0.7% | +2.1% | -1.1% | -2.8% | -3.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.93 | +3.7% | -0.7% | +2.1% | -1.1% | -2.8% | -3.4% |
| Dec 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.04 | $1.05 | +1.0% | -3.8% | +1.0% | +3.0% | +6.7% | -5.4% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $1.39 | $1.38 | -0.7% | +5.0% | -1.4% | +2.1% | -4.1% | -5.7% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.45 | +9.0% | +4.5% | +5.0% | -1.4% | +2.1% | -4.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.63 | +4.5% | +6.4% | -3.0% | +6.2% | -1.8% | +6.5% |
| Jun 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.13 | $3.20 | +2.2% | +0.6% | -5.7% | -9.4% | +6.3% | -6.3% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $2.95 | -1.0% | +2.3% | -1.6% | +0.7% | -2.6% | +13.9% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.05 | +0.3% | +3.0% | -4.2% | +5.0% | -1.9% | +1.3% |
| Apr 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.05 | $4.01 | -1.0% | -3.5% | -6.1% | -14.4% | -9.6% | +4.9% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.51 | $4.81 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% |
| Mar 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.51 | $4.81 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.19 | +1.9% | +8.4% | +2.1% | -1.3% | +11.9% | +1.1% |
| Aug 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.39 | $2.53 | +5.9% | +5.0% | -3.6% | +0.8% | +1.6% | -0.4% |
| Aug 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | EF Hutton | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.37 | $3.42 | +1.5% | -2.7% | +0.9% | -3.9% | -2.5% | +2.9% |
| Apr 17 | EF Hutton | Maintains | Buy → Buy | — | $3.11 | $3.20 | +2.9% | +1.3% | -2.2% | +2.3% | -1.6% | -1.9% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.98 | $4.00 | +0.5% | -3.0% | +2.1% | -4.6% | -5.3% | -2.0% |
| Jan 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | EF Hutton | Maintains | Buy → Buy | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.00 | $10.85 | -1.4% | -2.3% | -6.0% | +0.9% | +4.7% | +2.5% |
| May 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.86 | $9.07 | +2.4% | +2.5% | -3.2% | -4.4% | +1.3% | +4.1% |
| Apr 29 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.03 | $11.77 | -2.2% | -0.1% | +2.4% | +0.6% | +0.1% | -14.0% |
| Nov 19 | SVB Leerink | Maintains | Outperform → Outperform | — | $20.95 | $20.79 | -0.8% | -1.6% | -17.6% | +4.2% | +1.4% | -4.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Carr Douglas | SVP Finance & Operations | Sell | 275 | $1.98 | $544 | 504,819 | -3.06% | -4.85% |
| Jun 12, 2026 | Carr Douglas | SVP Finance & Operations | Sell | 1,654 | $2.23 | $4K | 505,094 | -5.22% | +4.78% |
| Jun 12, 2026 | Russotti Gregory | See Remarks | Sell | 2,584 | $2.23 | $6K | 512,319 | -5.22% | +4.78% |
| Jun 8, 2026 | Carr Douglas | SVP Finance & Operations | Sell | 249 | $2.11 | $526 | 506,748 | -4.07% | -5.22% |
| Jun 8, 2026 | Russotti Gregory | See Remarks | Sell | 524 | $2.11 | $1K | 514,903 | -4.07% | -5.22% |
| May 4, 2026 | Carr Douglas | SVP Finance & Operations | Sell | 264 | $2.34 | $618 | 506,997 | -1.28% | -0.44% |
8-K · 2.02
!! High
Century Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 12
8-K · 2.02
!! High
Century Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Innocence is activating its shelf registration to conduct an at-the-market offering, potentially diluting existing shareholders while raising capital for operations or strategic purposes.
Mar 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Century Therapeutics disclosed material information via press release and investor presentation on March 12, 2026, which investors should review for potential operational updates, clinical trial results, or strategic announcements affecting stock valuation.
Mar 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 8,695,652 | $20M | New | Mar 2026 |
| 2 | Point72 Asset Management | 5,964,678 | $13M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,686,204 | $13M | New | Mar 2026 |
| 4 | Millennium Management | 4,667,063 | $11M | Added | Mar 2026 |
| 5 | Woodline Partners Lp | 3,043,478 | $7M | New | Mar 2026 |
| 6 | Trails Edge Capital Partners, Lp | 2,449,993 | $6M | New | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 2,371,430 | $5M | Added | Mar 2026 |
| 8 | Renaissance Technologies Llc | 906,827 | $2M | Reduced | Mar 2026 |
| 9 | Marshall Wace, Llp | 673,584 | $2M | New | Mar 2026 |
| 10 | Acadian Asset Management Llc | 278,075 | $627K | Reduced | Mar 2026 |
| 11 | Northern Trust Corp | 230,820 | $522K | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 226,687 | $512K | Added | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 145,099 | $328K | Added | Mar 2026 |
| 14 | Barclays Plc | 120,232 | $272K | Added | Mar 2026 |
| 15 | Superstring Capital Management Lp | 119,308 | $270K | Reduced | Mar 2026 |
| 16 | Raymond James Financial Inc | 91,323 | $206K | — | Mar 2026 |
| 17 | Invesco Ltd. | 62,109 | $140K | New | Mar 2026 |
| 18 | Prudential Financial Inc | 25,300 | $57K | Reduced | Mar 2026 |
| 19 | Jane Street Group, Llc | 45,194 | $45K | Reduced | Dec 2025 |
| 20 | Ubs Group Ag | 14,215 | $32K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 249,719 | $579K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 200,453 | $491K | May 2026 |
| 3 | Fidelity Series Total Market Index Fund | 164,276 | $402K | May 2026 |
| 4 | LVIP State Street Small-Cap Index Fund | 90,500 | $222K | Jun 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 94,419 | $219K | Feb 2026 |
| 6 | Small-Cap Index Portfolio | 34,920 | $86K | Jun 2026 |
| 7 | U.S. MICRO CAP PORTFOLIO | 26,905 | $62K | Apr 2026 |
| 8 | Avantis U.S. Small Cap Equity ETF | 19,866 | $46K | Feb 2026 |
| 9 | PD Small-Cap Value Index Portfolio | 8,621 | $21K | Jun 2026 |
| 10 | Small-Cap Equity Portfolio | 4,978 | $12K | Jun 2026 |
| 11 | Knights of Columbus U.S. ALL CAP INDEX FUND | 244 | $464 | Jan 2026 |
| 12 | Guggenheim Active Allocation Fund | 96 | $223 | Feb 2026 |
Valuation
Market Cap
$169.7M
Enterprise Value
$52.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.10x
P/B
1.07x
P/S
—
P/FCF
-1.62x
EV/EBITDA
—
Shares Out
86.6M
Financials (TTM)
Revenue
$0
Net Income
-$109.8M
EBITDA
-$97.1M
Free Cash Flow
-$104.7M
Op Cash Flow
-$103.9M
EPS Basic
$-0.11
EPS Diluted
$-1.04
EPS Forward
$-0.63
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$223.7M
Total Liab.
$64.8M
Total Equity
$158.9M
Cash
$117.1M
LT Debt
$0
Book Value/Sh
$1.84
Debt/Equity
0.27x
Current Ratio
5.97
Quick Ratio
5.97
Returns & Growth
ROE
-6.0%
ROA
-4.3%
ROIC
-7.2%
Rev Growth YoY
+1556.8%
EPS Growth YoY
+93.2%
Price Returns
2W
-3.0%
1M
-12.9%
3M
-14.4%
6M
+12.0%
12M
+278.4%
Technicals
52W High
$3.04
52W Low
$0.43
50d MA
$2.19
200d MA
$1.82
RSI (14)
39.20
ATR (14)
$0.12
Beta
1.67
Avg Volume
895K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$4.00
Low
$2.00
Median
$3.00
Data updated apr 25, 2026 4:07pm
· Source: financialmodelingprep.com